More Weight Loss Solutions

Versartis, Inc. (NASDAQ:VSAR) Stock Closed 8.1% Above Its 50 Day Moving Average – Modern Readers

Aug 28th, 2017

Advertisement

Shares are trading at $19.15 which is marginally over $17.71, the stocks 50 day moving average and which is slightly above the 200 day moving average of $18.21. The 50 day moving average went up $1.44 or +8.14% and the 200 day average went up $0.94 or +5.16%. 268K shares changed hands on Friday. Overall, volume was up 43.13% over the stocks normal daily volume.

These firms have also modified their investment in VSAR. BNP Paribas Arbitrage, SA grew its stake by buying 3,333 shares an increase of 1,286.9%. BNP Paribas Arbitrage, SA now holds 3,592 shares worth $62,680,000. The total value of its holdings increased 1,253,500.0%. Renaissance Technologies LLC expanded its investment by buying 147,810 shares an increase of 68.8% in the quarter. Renaissance Technologies LLC currently owns 362,510 shares valued at $6,326,000. The value of the position overall is up by 38.0%.

Artal Group S.a. added to its position by buying 50,000 shares an increase of 16.7% as of 06/30/2017. Artal Group S.a. now controls 350,000 shares with a value of $6,108,000. The total value of its holdings decreased 4.6%. As of the end of the quarter Alliancebernstein L.P. had bought a total of 28,080 shares growing its holdings by 59.6%. The value of the investment in Versartis, Inc. increased from $1,006,000 to $1,312,000 increasing 30.4% quarter over quarter.

The company is trading up by 1.06% since yesterdays close of $18.95. In the last earnings report the EPS was $-3.45 and is expected to be $-3.49 for the current year with 35,578,000 shares now outstanding. Next quarters EPS is forecasted to be $-0.84 and the next full year EPS is anticipated to be $-3.04.

Versartis, Inc., launched on December 10, 2008, is an endocrine-focused biopharmaceutical company. The Company is involved in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Businesss first indication for somavaratan is pediatric GHD..

See the rest here:
Versartis, Inc. (NASDAQ:VSAR) Stock Closed 8.1% Above Its 50 Day Moving Average - Modern Readers

Related Posts

Contact One Of Our Consultants Today


Your Full Name
Your Email
Your Phone Number
Select your age (30+ only)
Confirm over 30 years old  Yes
Confirm that you are a US Citizen  Yes
This is a Serious Inquiry  Yes
Select A Program
Duration
Select Your US State
captcha Please Enter Code:


Tags:
Comments are closed.
Weight Loss Solutions
matomo tracker